Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Ventilation 11% ICU admission -72% c19rmd.com Elec et al. Remdesivir for COVID-19 LATE TREATMENT Favors remdesivir Favors control
Elec, 165 patient remdesivir late treatment study: 19% lower mortality [p=0.66], 11% lower ventilation [p=0.73], and 72% higher ICU admission [p=0.01] https://c19p.org/elec
copied to clipboard
COVID-19 and Kidney Transplantation: The impact of remdesivir on renal function and outcome - a retrospective cohort study
Elec et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.03.015
14 Mar 2022    Source   PDF   Share   Tweet
Retrospective 165 hospitalized COVID-19+ kidney transplant patients, 38 treated with remdesivir, showing no significant difference in mortality, higher ICU admission, and lower ICU mortality. Subject to confounding by time with significant changes to SOC and treatment propensity during the study period.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 19.3% lower, RR 0.81, p = 0.66, treatment 7 of 38 (18.4%), control 29 of 127 (22.8%), NNT 23.
risk of mechanical ventilation, 10.9% lower, RR 0.89, p = 0.73, treatment 8 of 38 (21.1%), control 30 of 127 (23.6%), NNT 39.
risk of ICU admission, 71.9% higher, RR 1.72, p = 0.01, treatment 18 of 38 (47.4%), control 35 of 127 (27.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.
Elec et al., 3/14/2022, retrospective, Romania, Europe, peer-reviewed, 9 authors, study period 1 March, 2020 - 31 May, 2021.
All Studies   All Outcomes
This PaperRemdesivirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit